MedTrace Logo

Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T

NCT05760599 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-03-08

No results posted yet for this study

Summary

To explore the efficacy and safety of candonilimab plus bevacizumab for patients with advanced hepatocellular carcinoma who progressed on atezolizumab plus bevacizumab.

Conditions

Interventions

DRUG

Candonilimab

10mg/kg, iv.drip, every 3 week

DRUG

Bevacizumab

15mg/kg, iv.drip, every 3 week

Sponsors & Collaborators

  • Shi Ming

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-27
Primary Completion
2024-01-01
Completion
2024-07-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05760599 on ClinicalTrials.gov